These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9886251)

  • 1. Soluble complement receptor 1 is increased in patients with leukemia and after administration of granulocyte colony-stimulating factor.
    Sadallah S; Lach E; Schwarz S; Gratwohl A; Spertini O; Schifferli JA
    J Leukoc Biol; 1999 Jan; 65(1):94-101. PubMed ID: 9886251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating soluble CR1 (CD35). Serum levels in diseases and evidence for its release by human leukocytes.
    Pascual M; Duchosal MA; Steiger G; Giostra E; Pechère A; Paccaud JP; Danielsson C; Schifferli JA
    J Immunol; 1993 Aug; 151(3):1702-11. PubMed ID: 8335953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble complement receptor type 1 (CD35) is released from leukocytes by surface cleavage.
    Danielsson C; Pascual M; French L; Steiger G; Schifferli JA
    Eur J Immunol; 1994 Nov; 24(11):2725-31. PubMed ID: 7957565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low levels of plasma soluble complement receptor type 1 in patients receiving thrombolytic therapy for acute myocardial infarction.
    Karthikeyan G; Baalasubramanian S; Seth S; Das N
    J Thromb Thrombolysis; 2007 Apr; 23(2):115-20. PubMed ID: 17131173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble complement receptor type 1 (CD35) in bronchoalveolar lavage of inflammatory lung diseases.
    Hamacher J; Sadallah S; Schifferli JA; Villard J; Nicod LP
    Eur Respir J; 1998 Jan; 11(1):112-9. PubMed ID: 9543279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of growth factors in the treatment of acute myeloid and lymphoblastic leukemia.
    Ottmann OG; Bug G; Krauter J
    Semin Hematol; 2007 Jul; 44(3):183-92. PubMed ID: 17631182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble complement receptor 1 inhibits both complement and granulocyte activation during ex vivo hemodialysis.
    Himmelfarb J; McMonagle E; Holbrook D; Toth C
    J Lab Clin Med; 1995 Oct; 126(4):392-400. PubMed ID: 7561449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effects of soluble CR1 in complement- and neutrophil-mediated tissue injury.
    Mulligan MS; Yeh CG; Rudolph AR; Ward PA
    J Immunol; 1992 Mar; 148(5):1479-85. PubMed ID: 1311349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) in serum in bone marrow transplanted patients.
    Sallerfors B; Olofsson T; Lenhoff S
    Bone Marrow Transplant; 1991 Sep; 8(3):191-5. PubMed ID: 1720339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia.
    Demirer T; Buckner CD; Appelbaum FR; Petersen FB; Rowley S; Weaver CH; Lilleby K; Sanders J; Chauncey T; Storb R
    Bone Marrow Transplant; 1995 Jun; 15(6):915-22. PubMed ID: 7581091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
    Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, PIXY-321, stem cell factor, interleukin-3, and interleukin-7: receptor binding and effects on clonogenic proliferation in acute lymphoblastic leukemia.
    Drach D; Estrov Z; Zhao S; Drach J; Cork A; Collins D; Kantarjian H; Andreeff M
    Leuk Lymphoma; 1994 Dec; 16(1-2):79-88. PubMed ID: 7535143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor.
    Makrides SC; Nygren PA; Andrews B; Ford PJ; Evans KS; Hayman EG; Adari H; Uhlén M; Toth CA
    J Pharmacol Exp Ther; 1996 Apr; 277(1):534-42. PubMed ID: 8613964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
    Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of priming with recombinant human granulocyte colony-stimulating factor on conditioning regimen for high-risk acute myeloid leukemia patients undergoing human leukocyte antigen-haploidentical hematopoietic stem cell transplantation: a multicenter randomized controlled study in southwest China.
    Gao L; Wen Q; Chen X; Liu Y; Zhang C; Gao L; Kong P; Zhang Y; Li Y; Liu J; Wang Q; Su Y; Wang C; Wang S; Zeng Y; Sun A; Du X; Zeng D; Liu H; Peng X; Zhang X
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):1932-9. PubMed ID: 25109850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of mast cell growth factor on acute myeloid leukemia cells in vitro: effects of combinations with other cytokines.
    Budel LM; Delwel R; van Buitenen C; Hoogerbrugge H; Löwenberg B
    Leukemia; 1993 Mar; 7(3):426-34. PubMed ID: 7680401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of the alternative complement pathway by sCR1[desLHR-A] protects the rabbit isolated heart from human complement-mediated damage.
    Gralinski MR; Wiater BC; Assenmacher AN; Lucchesi BR
    Immunopharmacology; 1996 Sep; 34(2-3):79-88. PubMed ID: 8886851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased serum levels of granulocyte colony-stimulating factor after autologous bone marrow or blood stem cell transplantation.
    Haas R; Gericke G; Witt B; Cayeux S; Hunstein W
    Exp Hematol; 1993 Jan; 21(1):109-13. PubMed ID: 7678083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monocyte-macrophages, granulocyte-macrophage colony-stimulating factor, and prolonged survival among patients with acute myeloid leukemia and stem cell transplants.
    Giles FJ
    Clin Infect Dis; 1998 Jun; 26(6):1282-9. PubMed ID: 9636847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.